Mishima, Saori
Taniguchi, Hiroya
Akagi, Kiwamu
Baba, Eishi
Fujiwara, Yutaka
Hirasawa, Akira
Ikeda, Masafumi
Maeda, Osamu
Muro, Kei
Nishihara, Hiroshi
Nishiyama, Hiroyki
Takano, Tadao
Tsuchihara, Katsuya
Yatabe, Yasushi
Kodera, Yasuhiro
Yoshino, Takayuki
Funding for this research was provided by:
Japan Agency for Medical Research and Development (18ck0106233h0003)
Ministry of Health, Labour and Welfare (public-013)
Article History
Received: 10 June 2019
Accepted: 16 June 2019
First Online: 8 July 2019
Compliance with ethical standards
:
: BE received honoraria from Eli Lilly and Chugai; and research funding from MSD, Ono, Taiho, Takeda, Eli Lilly, and Merck Serono. FY received honoraria from AstraZeneca, Bristol-Myers Squibb, and ONO; and research funding from Abbvie, AstraZeneca, BMS, Daiichi-Sankyo, Eisai, Incyte, Merck Serono, MSD, and Novartis. IM received honoraria from Bayer, Eisai, Taiho, and Novartis; and research funding from Ono, AstraZeneca, Taiho, Merck Serono, Bayer, Yakult, Kyowa Hakko Kirin, Eisai, Eli Lilly, Baxter, ASLAN, Nano Carrier, Chugai, Novartis, Bristol-Myers Squibb, and Cmic. KY received honoraria from Taiho, Ono, MSD, and Bristol-Myers Squibb; and research funding from Taiho, Ono, and MSD. MO reports research funding from Eli Lilly. MK received honoraria from Chugai, Takeda, Eli Lilly, Taiho, Ono, Bayer, Sanofi, and Bristol-Myers Squibb; and research funding from Gilead Sciences, Merck Serono, MSD, Daiichi Sankyo, Sanofi, Ono, Shionogi, Pfizer, and Kyowa Hakko Kirin. TH received honoraria from Takeda, Taiho, Chugai, and Eli Lilly; and research funding from Takeda. TT received honoraria from Bayer and Taiho. TY reports research funding from Novartis, MSD, Sumitomo Dainippon Pharma, Chugai, Sanofi, Daiichi-Sankyo, Parexel, and Ono. YY received honoraria from Chugai, MSD, Pfizer, Novartis, AstraZeneca and BMS. AK, HA, MS, NH, NH, and TK report no potential conflicts of interest.